

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. )**

---

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement  
 **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**  
 Definitive Proxy Statement  
 Definitive Additional Materials  
 Soliciting Material under § 240.14a-12

**NovoCure Limited**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.  
 Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies:  
\_\_\_\_\_
- (2) Aggregate number of securities to which transaction applies:  
\_\_\_\_\_
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):  
\_\_\_\_\_
- (4) Proposed maximum aggregate value of transaction:  
\_\_\_\_\_
- (5) Total fee paid:  
\_\_\_\_\_
- Fee paid previously with preliminary materials.  
 Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
- (1) Amount Previously Paid:  
\_\_\_\_\_
- (2) Form, Schedule or Registration Statement No.:  
\_\_\_\_\_
- (3) Filing Party:  
\_\_\_\_\_
- (4) Date Filed:  
\_\_\_\_\_
- 
-



## Your **Vote** Counts!

NOVOCURE LIMITED

2021 Annual Meeting  
Vote by June 6, 2021 11:59 PM ET



NOVOCURE LIMITED  
ATTENTION: SECURITIES DEPARTMENT  
3000 CENTRE STREET  
JERSEY CITY, NJ 07310

0000000000

### You invested in **NOVOCURE LIMITED** and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 9, 2021.**

### Get informed before you vote

View the Notice and Proxy Statement, Annual Report and Form 10-K on the OK you can receive a free paper or email copy of the materials by requesting print or May 26, 2021. If you would like to request a copy of the materials (1) for this and/or future shareholder meetings, you may (1) visit [www.proxyvote.com](http://www.proxyvote.com), (2) call 1-800-679-1559 or (3) send an email to [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com). If sending an email, please include your control number (indicated below in the Subject line). Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit [www.ProxyVote.com](http://www.ProxyVote.com)

Control #

#### Smartphone users

Point your camera here and  
vote without entering a  
control number



#### Vote in Person at the Meeting\*

June 9, 2021  
9:00 AM -

Novocure, Inc. (the  
Second Floor, Box 4 The Forum  
Greenleaf Street  
Suite 1000 07410  
Jersey Channel Islands

\*These are the meeting materials for proxy voting purposes. At the meeting, you will need to register before you will be able to

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommends
1. Election of Directors	
<b>Nominees:</b>	
1a. Asaf Danziger	✓ For
1b. William Doyle	✓ For
1c. Jeryl Hillerman	✓ For
1d. David Hung	✓ For
1e. Kinyp Gabriel Leung	✓ For
1f. Martin Madden	✓ For
1g. Sheryl McCoy	✓ For
1h. Timothy Scannell	✓ For
1i. William Vernon	✓ For
2. The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kest Lerer Garbay & Kaserer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2021.	✓ For
3. A non-binding advisory vote to approve executive compensation.	✓ For

**NOTE:** Such other business as may properly come before the meeting or any adjournment thereof.